PMID- 3129991
OWN - NLM
STAT- MEDLINE
DCOM- 19880603
LR  - 20210526
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 32
IP  - 3
DP  - 1988 Mar
TI  - In vitro and in vivo Phlebovirus inhibition by ribavirin.
PG  - 331-6
AB  - Ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was markedly 
      inhibitory in vitro to Adames and Balliet strains of Punta Toro virus (PTV), a 
      Phlebovirus related to Rift Valley fever and sandfly fever viruses. By using 
      inhibition of viral cytopathic effect in LLC-MK2 cells with both virus strains, 
      the 50% effective dose was 4 to 10 micrograms/ml and the virus rating was 1.3. 
      The Adames strain of PTV infection in mice was established for evaluation of the 
      in vivo antiviral efficacy of ribavirin. The drug was administered subcutaneously 
      (s.c.) twice daily for 5 to 7 days beginning 4 h pre-virus inoculation, 24 h 
      post-virus inoculation, or 36 h post-virus inoculation, with increased survivors, 
      reduced hepatic icterus, reduction of serum glutamic oxalic acid transaminase and 
      serum glutamic pyruvic acid transaminase, and inhibition of infectious virus from 
      sera and livers of infected mice. The minimum effective dose was 4.7 mg/kg per 
      day, with a maximum tolerated dose of 75 mg/kg per day. When the same treatment 
      schedule beginning 4 h pre-virus inoculation, 4 h post-virus inoculation, or 24 h 
      post-virus inoculation was used, orally administered ribavirin was effective at 
      doses as low as 6.3 mg/kg per day. Single s.c. ribavirin treatments at doses of 
      175 to 700 mg/kg administered from 4 to 48 h post-virus inoculation were also 
      effective. No effect was seen when ribavirin was administered s.c. to mice 
      infected intracerebrally with the PTV strain Balliet, even though treatment was 
      begun 36 h before virus exposure.
FAU - Sidwell, R W
AU  - Sidwell RW
AD  - Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan 
      84322-5600.
FAU - Huffman, J H
AU  - Huffman JH
FAU - Barnett, B B
AU  - Barnett BB
FAU - Pifat, D Y
AU  - Pifat DY
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Ribonucleosides)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Animals
MH  - Brain Diseases/drug therapy
MH  - Bunyaviridae/*drug effects
MH  - Bunyaviridae Infections/*drug therapy
MH  - Female
MH  - Injections, Subcutaneous
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Ribavirin/administration & dosage/*pharmacology/therapeutic use
MH  - Ribonucleosides/*pharmacology
MH  - Time Factors
PMC - PMC172170
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
PMCR- 1988/03/01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
PHST- 1988/03/01 00:00 [pmc-release]
AID - 10.1128/AAC.32.3.331 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 1988 Mar;32(3):331-6. doi: 10.1128/AAC.32.3.331.